Athira Pharma Logo RGB@1200px.jpg
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
June 12, 2024 07:00 ET | Athira Pharma, Inc.
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
Vaccinex logo
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
June 06, 2024 08:30 ET | Vaccinex, Inc.
Patient visits complete in Alzheimer's Disease clinical trial. Company plans to lock database in June and to present topline data in July.
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma to Participate in Upcoming June Conferences
May 29, 2024 07:00 ET | Athira Pharma, Inc.
BOTHELL, Wash., May 29, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Vaccinex logo
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 15, 2024 18:00 ET | Vaccinex, Inc.
Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease in early June 2024. $8.2 million of new financing in Q1.
SECU Foundation Awar
SECU Foundation Awards MemoryCare $250,000 to Expand Dementia Care in Rural Western North Carolina
May 06, 2024 10:37 ET | State Employees' Credit Union (SECU)
SECU Foundation awarded $250,000 to MemoryCare for the expansion of dementia care and in-home clinical and care management services in rural Western N.C.
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma to Participate in Upcoming May Conferences
May 02, 2024 07:00 ET | Athira Pharma, Inc.
BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
UAA.png
UsAgainstAlzheimer’s Launches 2024 Brain Health Academy
April 16, 2024 10:48 ET | UsAgainstAlzheimer's
WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- UsAgainstAlzheimer’s today announced the return of its Brain Health Academy, scheduled to begin on May 9, 2024. First launched in 2022, the Academy...
Longeveron Logo.jpg
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
April 15, 2024 08:30 ET | Longeveron
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
April 03, 2024 07:00 ET | Athira Pharma, Inc.
BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal...
Vaccinex logo
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
April 02, 2024 08:30 ET | Vaccinex, Inc.
Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024.